370 related articles for article (PubMed ID: 29486482)
1. CHK2 Promotes Anoikis and is Associated with the Progression of Papillary Thyroid Cancer.
Zhao W; Chen S; Hou X; Chen G; Zhao Y
Cell Physiol Biochem; 2018; 45(4):1590-1602. PubMed ID: 29486482
[TBL] [Abstract][Full Text] [Related]
2. LncRNA SNHG12 promotes the proliferation and metastasis of papillary thyroid carcinoma cells through regulating wnt/β-catenin signaling pathway.
Ding S; Qu W; Jiao Y; Zhang J; Zhang C; Dang S
Cancer Biomark; 2018; 22(2):217-226. PubMed ID: 29630517
[TBL] [Abstract][Full Text] [Related]
3. USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma.
Jia M; Guo Y; Lu X
Cell Physiol Biochem; 2018; 45(5):2044-2053. PubMed ID: 29533940
[TBL] [Abstract][Full Text] [Related]
4. RASSF10 is Epigenetically Inactivated and Suppresses Cell Proliferation and Induces Cell Apoptosis by Activating the p53 Signalling Pathway in Papillary Thyroid Carcinoma Cancer.
Fan C; Wang W; Jin J; Yu Z; Xin X
Cell Physiol Biochem; 2017; 41(3):1229-1239. PubMed ID: 28268222
[TBL] [Abstract][Full Text] [Related]
5. Solute carrier family 35 member F2 is indispensable for papillary thyroid carcinoma progression through activation of transforming growth factor-β type I receptor/apoptosis signal-regulating kinase 1/mitogen-activated protein kinase signaling axis.
He J; Jin Y; Zhou M; Li X; Chen W; Wang Y; Gu S; Cao Y; Chu C; Liu X; Zou Q
Cancer Sci; 2018 Mar; 109(3):642-655. PubMed ID: 29274137
[TBL] [Abstract][Full Text] [Related]
6. Long Noncoding RNA HOXA-AS2 Promotes Papillary Thyroid Cancer Progression by Regulating miR-520c-3p/S100A4 Pathway.
Xia F; Chen Y; Jiang B; Du X; Peng Y; Wang W; Huang W; Feng T; Li X
Cell Physiol Biochem; 2018; 50(5):1659-1672. PubMed ID: 30384358
[TBL] [Abstract][Full Text] [Related]
7. MiR-20b Displays Tumor-Suppressor Functions in Papillary Thyroid Carcinoma by Regulating the MAPK/ERK Signaling Pathway.
Hong S; Yu S; Li J; Yin Y; Liu Y; Zhang Q; Guan H; Li Y; Xiao H
Thyroid; 2016 Dec; 26(12):1733-1743. PubMed ID: 27717302
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of CSN6 attenuates papillary thyroid carcinoma progression by reducing Wnt/β-catenin signaling and sensitizes cancer cells to FH535 therapy.
Wen D; Liao T; Ma B; Qu N; Shi RL; Lu ZW; Wang YL; Wei WJ; Ji QH
Cancer Med; 2018 Feb; 7(2):285-296. PubMed ID: 29341469
[TBL] [Abstract][Full Text] [Related]
9. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
[TBL] [Abstract][Full Text] [Related]
10. PDLIM5 identified by label-free quantitative proteomics as a potential novel biomarker of papillary thyroid carcinoma.
Wei X; Zhang Y; Yu S; Li S; Jiang W; Zhu Y; Xu Y; Yang C; Tian G; Mi J; Bergquist J; Zhao M; Song F
Biochem Biophys Res Commun; 2018 May; 499(2):338-344. PubMed ID: 29574154
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of lncRNA-ATB by Transforming Growth Factor β1 (TGF-β1) Promotes Migration and Invasion of Papillary Thyroid Carcinoma Cells.
Cui M; Chang Y; Du W; Liu S; Qi J; Luo R; Luo S
Med Sci Monit; 2018 Jul; 24():5152-5158. PubMed ID: 30042377
[TBL] [Abstract][Full Text] [Related]
12. LncRNA LINC00673 inhibits p53 expression by interacting with EZH2 and DNMT1 in papillary thyroid carcinoma.
Meng XF; Zhao LY; Chu XF
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2075-2083. PubMed ID: 30915752
[TBL] [Abstract][Full Text] [Related]
13. Tumor suppressor protein kinase Chk2 is a mediator of anoikis of intestinal epithelial cells.
Yoo BH; Berezkin A; Wang Y; Zagryazhskaya A; Rosen KV
Int J Cancer; 2012 Jul; 131(2):357-66. PubMed ID: 21834075
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-150 targets Rho-associated protein kinase 1 to inhibit cell proliferation, migration and invasion in papillary thyroid carcinoma.
Cheng L; Zhou R; Chen M; Feng L; Li H
Mol Med Rep; 2017 Aug; 16(2):2217-2224. PubMed ID: 28656254
[TBL] [Abstract][Full Text] [Related]
15. MiR-577 inhibits papillary thyroid carcinoma cell proliferation, migration and invasion by targeting SphK2.
Xue KC; Hu DD; Zhao L; Li N; Shen HY
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(17):3794-3800. PubMed ID: 28975989
[TBL] [Abstract][Full Text] [Related]
16. miR-199a-5p inhibits the progression of papillary thyroid carcinoma by targeting SNAI1.
Ma S; Jia W; Ni S
Biochem Biophys Res Commun; 2018 Feb; 497(1):181-186. PubMed ID: 29427661
[TBL] [Abstract][Full Text] [Related]
17. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-663 suppresses cell invasion and migration by targeting transforming growth factor beta 1 in papillary thyroid carcinoma.
Wang Z; Zhang H; Zhang P; Dong W; He L
Tumour Biol; 2016 Jun; 37(6):7633-44. PubMed ID: 26687649
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma.
Chou CK; Yang KD; Chou FF; Huang CC; Lan YW; Lee YF; Kang HY; Liu RT
J Clin Endocrinol Metab; 2013 Feb; 98(2):E196-205. PubMed ID: 23264400
[TBL] [Abstract][Full Text] [Related]
20. FOXE1 supports the tumor promotion of Gli2 on papillary thyroid carcinoma by the Wnt/β-catenin pathway.
Ma J; Huang X; Li Z; Shen Y; Lai J; Su Q; Zhao J; Xu J
J Cell Physiol; 2019 Aug; 234(10):17739-17748. PubMed ID: 30793770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]